BCAB
Price
$0.21
Change
+$0.02 (+10.53%)
Updated
Feb 6 closing price
Capitalization
13.33M
39 days until earnings call
Intraday BUY SELL Signals
ENTX
Price
$1.04
Change
-$0.13 (-11.11%)
Updated
Feb 6 closing price
Capitalization
48.61M
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCAB vs ENTX

Header iconBCAB vs ENTX Comparison
Open Charts BCAB vs ENTXBanner chart's image
BioAtla
Price$0.21
Change+$0.02 (+10.53%)
Volume$3M
Capitalization13.33M
Entera Bio
Price$1.04
Change-$0.13 (-11.11%)
Volume$356.05K
Capitalization48.61M
BCAB vs ENTX Comparison Chart in %
BCAB
Daily Signal:
Gain/Loss:
ENTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BCAB vs. ENTX commentary
Feb 08, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAB is a Hold and ENTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 08, 2026
Stock price -- (BCAB: $0.21 vs. ENTX: $1.04)
Brand notoriety: BCAB and ENTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCAB: 124% vs. ENTX: 170%
Market capitalization -- BCAB: $13.33M vs. ENTX: $48.61M
BCAB [@Biotechnology] is valued at $13.33M. ENTX’s [@Biotechnology] market capitalization is $48.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.26B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCAB’s FA Score shows that 0 FA rating(s) are green whileENTX’s FA Score has 0 green FA rating(s).

  • BCAB’s FA Score: 0 green, 5 red.
  • ENTX’s FA Score: 0 green, 5 red.
According to our system of comparison, both BCAB and ENTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCAB’s TA Score shows that 5 TA indicator(s) are bullish while ENTX’s TA Score has 3 bullish TA indicator(s).

  • BCAB’s TA Score: 5 bullish, 4 bearish.
  • ENTX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BCAB is a better buy in the short-term than ENTX.

Price Growth

BCAB (@Biotechnology) experienced а -21.71% price change this week, while ENTX (@Biotechnology) price change was -24.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.30%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +31.79%.

Reported Earning Dates

BCAB is expected to report earnings on Mar 19, 2026.

ENTX is expected to report earnings on Mar 27, 2026.

Industries' Descriptions

@Biotechnology (-2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ENTX($48.6M) has a higher market cap than BCAB($13.3M). ENTX YTD gains are higher at: -46.392 vs. BCAB (-62.903). ENTX has higher annual earnings (EBITDA): -10.79M vs. BCAB (-65.71M). ENTX (8.57M) and BCAB (8.32M) have equal amount of cash in the bank . ENTX has less debt than BCAB: ENTX (211K) vs BCAB (6.18M). ENTX has higher revenues than BCAB: ENTX (124K) vs BCAB (0).
BCABENTXBCAB / ENTX
Capitalization13.3M48.6M27%
EBITDA-65.71M-10.79M609%
Gain YTD-62.903-46.392136%
P/E RatioN/AN/A-
Revenue0124K-
Total Cash8.32M8.57M97%
Total Debt6.18M211K2,929%
FUNDAMENTALS RATINGS
ENTX: Fundamental Ratings
ENTX
OUTLOOK RATING
1..100
70
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
95
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCABENTX
RSI
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BCAB
Daily Signal:
Gain/Loss:
ENTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BBOT10.700.55
+5.42%
BridgeBio Oncology Therapeutics Inc
BOOM8.150.30
+3.82%
DMC Global
HGV47.641.39
+3.01%
Hilton Grand Vacations
KGC32.090.84
+2.69%
Kinross Gold Corp
LEDS1.600.01
+0.31%
SemiLEDS Corp

BCAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAB has been closely correlated with ARTV. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if BCAB jumps, then ARTV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAB
1D Price
Change %
BCAB100%
+10.78%
ARTV - BCAB
84%
Closely correlated
+4.13%
VTGN - BCAB
82%
Closely correlated
+11.52%
QNCX - BCAB
80%
Closely correlated
-4.79%
MREO - BCAB
80%
Closely correlated
+13.20%
TPST - BCAB
80%
Closely correlated
+7.62%
More

ENTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTX has been closely correlated with VTGN. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ENTX jumps, then VTGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
-11.11%
VTGN - ENTX
73%
Closely correlated
+11.52%
MREO - ENTX
72%
Closely correlated
+13.20%
QNCX - ENTX
70%
Closely correlated
-4.79%
TPST - ENTX
69%
Closely correlated
+7.62%
BCAB - ENTX
68%
Closely correlated
+10.78%
More